XNAS · Biotechnology
Last stored close · Nov 9, 2026
Close · Nov 9, 2026
$74.74-1.64%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
31/100
Weak
Score components
TickerWhale View
Cg Oncology scores 31 out of 100 overall, which we rate weak. Risk is its strongest area and Valuation its weakest.
What helps
- Technical
- Risk
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
Quality & growth
30%7Weak
- Revenue growth 1032.7%
- EPS growth n/a
Valuation
25%1Weak
- P/E -29.4
- EV/Sales 1055.4
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#132 / 139sector rank by TickerWhale Score
TickerWhale Score 31 vs sector average 54.6 (-23.6)
Revenue growth (industry)Top 4%
Gross margin (industry)Top 100%
Return on equity (industry)Top 52%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
64/100Positive vs universe
Ranks 64th of 100 covered names on our technical composite — the composite itself scores 66/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
5 buy · 0 sell · 3 neutral of 8 votes
TickerWhale rates CGON's technical setup middling — 64th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+12.7%
- vs 50-day+9.5%
Momentum
Constructive
- RSI (14)65 · neutral
- Stochasticbuy
- CCIbuy
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength20· weak trend
- MACD (12,26,9)buy(histogram 1.719)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 0 sell · 3 neutral.
Result — 5 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-09 · revised_latestValuation multiples
- P/E (TTM)-29.4 · TTM loss
- P/S (TTM)1058.1
- P/B6.4
- EV/EBITDA—
- EV/Sales1055.4
- PEG—
Profitability & returns
- Gross margin-85.2%
- Net margin-3601.6%
- ROE-21.2%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)1032.7%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $6.6B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CGONCurrentCg Oncology | 31 | 66 | -29.4 | — | 6.4 | 1055.4 | $74.74 | -1.64% | +1032.7% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 82 | 102.1 | — | 12.6 | 9.7 | $98.76 | +5.22% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.8 | — | 5.2 | 1.6 | $289.00 | +2.00% | +7.5% | ||
| EXELExelixis | 77 | 89 | 21.6 | — | 10.1 | 7.5 | $71.74 | +3.12% | +9.2% | ||
| TGTXTG Therapeutics | 77 | 85 | 22.6 | — | 16.5 | 12.8 | $63.38 | +5.94% | +76.1% | ||
| OSCROscar Health Inc - | 74 | 66 | 19.5 | — | 5.2 | 0.5 | $32.14 | +4.86% | +43.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.